H Guan1, K M Chow, R Shah, C J Rhodes, L B Hersh. 1. Department of Molecular and Cellular Biochemistry, University of Kentucky, B236 Biomedical Biological Sciences Research Building, 741 South Limestone Street, Lexington, KY 40536-0509, USA. hguan2@uky.edu
Abstract
AIMS/HYPOTHESIS: A progressive loss of pancreatic beta cell function, a decrease in beta cell mass and accumulation of islet amyloid is characteristic of type 2 diabetes mellitus. The main constituent of islet amyloid is islet amyloid polypeptide (IAPP). In this study, we examined the ability of the peptidase neprilysin to cleave IAPP and prevent human IAPP-induced pancreatic beta cell toxicity. METHODS: Neprilysin and a catalytically compromised neprilysin mutant were tested for their ability to inhibit human IAPP fibrillisation and human IAPP-induced pancreatic beta cell cytotoxicity. Degradation of human IAPP by neprilysin was followed by HPLC, and the degradation products were identified by MS. RESULTS: Neprilysin prevented IAPP fibrillisation by cleaving IAPP at Arg(11)-Leu(12), Leu(12)-Ala(13), Asn(14)-Phe(15), Phe(15)-Leu(16), Asn(22)-Phe(23) and Ala(25)-Ile(26). It also appears to prevent human IAPP fibrillisation through a non-catalytic interaction. Neprilysin protected against beta cell cytotoxicity induced by exogenously added or endogenously produced human IAPP. CONCLUSIONS/ INTERPRETATION: The data presented support a potential therapeutic role for neprilysin in preventing type 2 diabetes mellitus. This study supports the hypothesis that extracellular human IAPP contributes to human IAPP-induced beta cell cytotoxicity. Whether human IAPP exerts its cytotoxic effect through a totally extracellular mechanism or through a cellular reuptake mechanism is unclear at this time.
AIMS/HYPOTHESIS: A progressive loss of pancreatic beta cell function, a decrease in beta cell mass and accumulation of islet amyloid is characteristic of type 2 diabetes mellitus. The main constituent of islet amyloid is islet amyloid polypeptide (IAPP). In this study, we examined the ability of the peptidase neprilysin to cleave IAPP and prevent humanIAPP-induced pancreatic beta cell toxicity. METHODS:Neprilysin and a catalytically compromised neprilysin mutant were tested for their ability to inhibit humanIAPP fibrillisation and humanIAPP-induced pancreatic beta cell cytotoxicity. Degradation of humanIAPP by neprilysin was followed by HPLC, and the degradation products were identified by MS. RESULTS:Neprilysin prevented IAPP fibrillisation by cleaving IAPP at Arg(11)-Leu(12), Leu(12)-Ala(13), Asn(14)-Phe(15), Phe(15)-Leu(16), Asn(22)-Phe(23) and Ala(25)-Ile(26). It also appears to prevent humanIAPP fibrillisation through a non-catalytic interaction. Neprilysin protected against beta cell cytotoxicity induced by exogenously added or endogenously produced humanIAPP. CONCLUSIONS/ INTERPRETATION: The data presented support a potential therapeutic role for neprilysin in preventing type 2 diabetes mellitus. This study supports the hypothesis that extracellular humanIAPP contributes to humanIAPP-induced beta cell cytotoxicity. Whether humanIAPP exerts its cytotoxic effect through a totally extracellular mechanism or through a cellular reuptake mechanism is unclear at this time.
Authors: A Clark; C A Wells; I D Buley; J K Cruickshank; R I Vanhegan; D R Matthews; G J Cooper; R R Holman; R C Turner Journal: Diabetes Res Date: 1988-12
Authors: A Devault; C Nault; M Zollinger; M C Fournie-Zaluski; B P Roques; P Crine; G Boileau Journal: J Biol Chem Date: 1988-03-15 Impact factor: 5.157
Authors: Daniel T Meier; Ling-Hsien Tu; Sakeneh Zraika; Meghan F Hogan; Andrew T Templin; Rebecca L Hull; Daniel P Raleigh; Steven E Kahn Journal: J Biol Chem Date: 2015-10-19 Impact factor: 5.157
Authors: Laale F Alawi; Sana E Emberesh; Brenda A Owuor; Harshita Chodavarapu; Rucha Fadnavis; Salim S El-Amouri; Khalid M Elased Journal: Physiol Rep Date: 2020-02